ru« co'«ot<'.
DmwłcrA im ((NMkUmnM]
Model in vitro
Mytar B i wsp. (1999,2003) Zonbala M i wsp. (1993,1994)
-75
Int C014* C014‘* CD147CD16*
p<0.05
g (ypiw *J ,*•# «Wv * •**.’.■»*» **’*>" tilnafam «pM «h ItM mttfjlh <1*. F«t S^iinJ i Cm’ miI
ółlfT-l wp«dkCWto'*;'»>*x<ł»li*.Jmmc«d»K MIIkM Th. urn :
Model in vitro
lOO-i | |||
90 - |
«** | ||
“ 80 | |||
£2 7o - |
_ •« •« | ||
B 60 - |
* O | ||
1 so |
a • a | ||
3 40 1 |
a a •• | ||
+ 30 |
a •• | ||
«0 | |||
-« r • j |
S 20 | ||
Mo w rozwoju nowotworu |
8 10 - |
It | |
o - |
CONTROL CONTROL PATIENT PATlENT | ||
<PRE> (MCSF) (PRE) (MCSF) | |||
fig 3. Spontannoun nl*vatton of thu CD16* monocyto populallon | |||
1 7 M 1)71ł/ł ) |
•nd anhanewi rMponil»«n«M to rtiMCSF In patiwit* włth 0»*tcoln- | ||
i in vLvu t |
taatlnałcardnoma. Monosytn wara Idantifiad ł»y Ughł-aeattar 0tla«. | ||
X / |
Tb* l*v*l of GDI6* monooytaa. axpraaaad aa tha paroantaga of total | ||
aft ar 11 days of rhMCSF traatmant. For compafl»on, data from tb» | |||
normal sutoiaeta atudiad In Rg 1 (labaUd contro!) aro aUo (hown | |||
balor* and |
uf lar 14 claya of rhMCSF traatmant. Tha uppor limit of | ||
normal for wontamout aapraailon of CD 16* monocYtai In our labo- | |||
rotory i* ihown na a daahad lin*. Both groupa słiowad a aiontfloant | |||
Inoraai* in CD16' monooytaa *ft*r rhMCSF traatmant oomparad wWh | |||
baafMIn* valuaa |F < .01 by Wtlooxon p*lrv«J rank *»»«>. and tha patlant | |||
group wat |
aionłfioarrtly hlghar thon tha control group in both pra- | ||
traatmant |
and on-th.r.py aamplaa (P -? .Ol by WllaoMon rank aum M0M17 | ||
tost). |